Federica Sotgia

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8534335/federica-sotgia-publications-by-year.pdf
Version: 2024-04-26

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210 papers	25,265 citations	82 h-index	156 g-index
214 ext. papers	28,553 ext. citations	5.8 avg, IF	6.73 L-index

#	Paper	IF	Citations
210	High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy. *Frontiers in Oncology*, **2021**, 11, 740720	5.3	7
209	Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. *Cell Death and Differentiation*, **2021**, 28, 2797-2817	12.7	7
208	MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity. *Frontiers in Oncology*, **2021**, 11, 678343	5.3	2
207	New insights in the expression of stromal caveolin 1 in breast cancer spread to axillary lymph nodes. *Scientific Reports*, **2021**, 11, 2755	4.9	2
206	Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production. *Cells*, **2020**, 9,	7.9	20
205	COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?. *Aging*, **2020**, 12, 6511-6517	5.6	123
204	First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds. *Aging*, **2020**, 12, 10162-10179	5.6	10
203	Using the common cold virus as a naturally occurring vaccine to prevent COVID-19: Lessons from Edward Jenner. *Aging*, **2020**, 12, 18797-18803	5.6	4
202	Essential role of STAT5a in DCIS formation and invasion following estrogen treatment. *Aging*, **2020**, 12, 15104-15120	5.6	1
201	Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin. *British Journal of Cancer*, **2020**, 122, 62-71	8.7	10
200	Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRPathway. *Cells*, **2020**, 9,	7.9	13
199	A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity. *Frontiers in Oncology*, **2020**, 10, 1528	5.3	5
198	Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity. *Frontiers in Oncology*, **2020**, 10, 1776	5.3	13
197	Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). *Aging*, **2019**, 11, 2202-2216	5.6	36
196	Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine). *Frontiers in Oncology*, **2019**, 9, 615	5.3	26
195	Hallmarks of the cancer cell of origin: Comparisons with "energetic" cancer stem cells (e-CSCs). *Aging*, **2019**, 11, 1065-1068	5.6	15
194	Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito-stemness and ribo-stemness features. *Aging*, **2019**, 11, 4801-4835	5.6	7

193	Thioalbamide, A Thioamidated Peptide from , Affects Tumor Growth and Stemness by Inducing Metabolic Dysfunction and Oxidative Stress. *Cells*, **2019**, 8,	7.9	23
192	FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer. *Cancers*, **2019**, 11,	6.6	11
191	"Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy. *Frontiers in Oncology*, **2018**, 8, 677	5.3	37
190	Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism. *Biochimica Et Biophysica Acta - Bioenergetics*, **2018**, 1859, 984-996	4.6	45
189	Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. *Biochemical Journal*, **2018**, 475, 1611-1634	3.8	135
188	The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy. *Aging*, **2018**, 10, 4000-4023	5.6	15
187	Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling. *Oncotarget*, **2018**, 9, 13254-13275	3.3	53
186	Azithromycin and Roxithromycin define a new family of "senolytic" drugs that target senescent human fibroblasts. *Aging*, **2018**, 10, 3294-3307	5.6	53
185	Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs). *Aging*, **2018**, 10, 229-240	5.6	22
184	Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways. *Aging*, **2018**, 10, 1867-1883	5.6	24
183	Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. *Frontiers in Oncology*, **2018**, 8, 452	5.3	71
182	A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. *Cell Cycle*, **2018**, 17, 2091-2100	4.7	36
181	Cancer metabolism: a therapeutic perspective. *Nature Reviews Clinical Oncology*, **2017**, 14, 11-31	19.4	659
180	Anti-CTLA-4 therapy for malignant mesothelioma. *Immunotherapy*, **2017**, 9, 273-280	3.8	15
179	Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. *Expert Opinion on Orphan Drugs*, **2017**, 5, 455-465	1.1	7
178	Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). *Oncotarget*, **2017**, 8, 67269-67286	3.3	54
177	GPER mediates the angiocrine actions induced by IGF1 through the HIF-1/VEGF pathway in the breast tumor microenvironment. *Breast Cancer Research*, **2017**, 19, 129	8.3	42
176	Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics. *Oncotarget*, **2017**, 8, 68730-68745	3.3	44

175	Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. *Oncotarget*, **2017**, 8, 67457-67472	3.3	23
174	Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer. *Oncotarget*, **2017**, 8, 20309-20327	3.3	43
173	Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy. *Oncotarget*, **2017**, 8, 56126-56142	3.3	39
172	Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. *Oncotarget*, **2017**, 8, 9868-9884	3.3	35
171	Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. *Seminars in Oncology*, **2017**, 44, 218-225	5.5	25
170	Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer. *Seminars in Oncology*, **2017**, 44, 226-232	5.5	30
169	G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	21
168	A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis. *Aging*, **2017**, 9, 2098-2116	5.6	12
167	Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy. *Aging*, **2017**, 9, 2610-2628	5.6	32
166	Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics. *Oncotarget*, **2017**, 8, 68095-68107	3.3	17
165	Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine. *Oncotarget*, **2017**, 8, 67117-67128	3.3	24
164	Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy. *Oncotarget*, **2017**, 8, 66925-66939	3.3	7
163	Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs). *Oncotarget*, **2017**, 8, 78340-78350	3.3	22
162	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
161	Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). *Aging*, **2016**, 8, 1593-607	5.6	83
160	Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. *Oncotarget*, **2016**, 7, 34084-99	3.3	127
159	Cancer stem cell metabolism. *Breast Cancer Research*, **2016**, 18, 55	8.3	261
158	Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia. *Blood*, **2016**, 128, 453-6	2.2	37

157	Caveolae and signalling in cancer. *Nature Reviews Cancer*, **2015**, 15, 225-37	31.3	135
156	Metastasis and Oxidative Stress: Are Antioxidants a Metabolic Driver of Progression?. *Cell Metabolism*, **2015**, 22, 956-8	24.6	64
155	Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose. *Oncoscience*, **2015**, 2, 696-9	0.8	20
154	Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via "differentiation-based nano-therapy". *Oncotarget*, **2015**, 6, 3553-62	3.3	150
153	Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment. *Oncotarget*, **2015**, 6, 14687-99	3.3	26
152	Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. *Oncotarget*, **2015**, 6, 14777-95	3.3	175
151	Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. *Oncotarget*, **2015**, 6, 4569-84	3.3	309
150	Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts. *Aging*, **2015**, 7, 816-38	5.6	25
149	Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. *Oncotarget*, **2015**, 6, 14005-25	3.3	76
148	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. *Oncotarget*, **2015**, 6, 30472-86	3.3	131
147	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. *Oncotarget*, **2015**, 6, 4585-601	3.3	46
146	Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. *Oncotarget*, **2015**, 6, 10728-45	3.3	68
145	Estrogen related receptor (ERR)a promising target for the therapy of adrenocortical carcinoma (ACC). *Oncotarget*, **2015**, 6, 25135-48	3.3	32
144	Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells. *Oncotarget*, **2015**, 6, 21892-905	3.3	33
143	Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. *Oncotarget*, **2015**, 6, 30453-71	3.3	84
142	Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. *Seminars in Cancer Biology*, **2014**, 25, 47-60	12.7	252
141	Metabolic asymmetry in cancer: a "balancing act" that promotes tumor growth. *Cancer Cell*, **2014**, 26, 5-7	24.3	15
140	Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. *Seminars in Oncology*, **2014**, 41, 195-216	5.5	141

139	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. *Cell Cycle*, **2014**, 13, 580-99	4.7	42
138	CAPER, a novel regulator of human breast cancer progression. *Cell Cycle*, **2014**, 13, 1256-64	4.7	14
137	17β-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells. *Oncotarget*, **2014**, 5, 3055-65	3.3	19
136	Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. *Oncotarget*, **2014**, 5, 11029-37	3.3	142
135	Cav1 suppresses tumor growth and metastasis in a murine model of cutaneous SCC through modulation of MAPK/AP-1 activation. *American Journal of Pathology*, **2013**, 182, 992-1004	5.8	23
134	Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?. *Seminars in Oncology*, **2013**, 40, 403-18	5.5	35
133	Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo. *Cell Cycle*, **2013**, 12, 480-90	4.7	23
132	Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. *Cell Cycle*, **2013**, 12, 1371-84	4.7	159
131	Caloric restriction augments radiation efficacy in breast cancer. *Cell Cycle*, **2013**, 12, 1955-63	4.7	65
130	Nutrient restriction and radiation therapy for cancer treatment: when less is more. *Oncologist*, **2013** , 18, 97-103	5.7	35
129	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. *Cell Cycle*, **2013**, 12, 818-25	4.7	42
128	Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide. *Cell Cycle*, **2013**, 12, 1510-20	4.7	41
127	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: implications for breast cancer prevention. *Cell Cycle*, **2013**, 12, 289-301	4.7	39
126	Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: therapeutic implications. *Cell Cycle*, **2013**, 12, 2534-5	4.7	2
125	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. *Cell Cycle*, **2013**, 12, 2935-6	4.7	11
124	Compartment-specific activation of PPARγ governs breast cancer tumor growth, via metabolic reprogramming and symbiosis. *Cell Cycle*, **2013**, 12, 1360-70	4.7	23
123	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4. *Cell Cycle*, **2013**, 12, 2580-97	4.7	65
122	Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. *Cell Cycle*, **2013**, 12, 2723-32	4.7	90

121	Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. *Cell Cycle*, **2013**, 12, 172-82	4.7	64
120	Cancer metabolism: new validated targets for drug discovery. *Oncotarget*, **2013**, 4, 1309-16	3.3	40
119	Cav1 inhibits benign skin tumor development in a two-stage carcinogenesis model by suppressing epidermal proliferation. *American Journal of Translational Research (discontinued)*, **2013**, 5, 80-91	3	6
118	Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. *Cell Cycle*, **2012**, 11, 4390-401	4.7	118
117	Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. *Cell Cycle*, **2012**, 11, 3956-63	4.7	89
116	Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. *Antioxidants and Redox Signaling*, **2012**, 16, 1264-84	8.4	222
115	Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. *Cell Cycle*, **2012**, 11, 1108-17	4.7	191
114	Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production. *Cell Cycle*, **2012**, 11, 3019-35	4.7	194
113	Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. *American Journal of Pathology*, **2012**, 181, 278-93	5.8	90
112	Power surge: supporting cells "fuel" cancer cell mitochondria. *Cell Metabolism*, **2012**, 15, 4-5	24.6	115
111	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	16.2	2783
110	Estrogen receptor beta (ERβ) produces autophagy and necroptosis in human seminoma cell line through the binding of the Sp1 on the phosphatase and tensin homolog deleted from chromosome 10 (PTEN) promoter gene. *Cell Cycle*, **2012**, 11, 2911-21	4.7	52
109	The milk protein β-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. *Cell Cycle*, **2012**, 11, 3972-82	4.7	23
108	Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. *Cell Cycle*, **2012**, 11, 1445-54	4.7	139
107	Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. *Cell Cycle*, **2012**, 11, 4174-80	4.7	88
106	Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1α, autophagy and ketone body production. *Cell Cycle*, **2012**, 11, 4167-73	4.7	32
105	Hyccin, the molecule mutated in the leukodystrophy hypomyelination and congenital cataract (HCC), is a neuronal protein. *PLoS ONE*, **2012**, 7, e32180	3.7	17
104	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. *Cell Cycle*, **2012**, 11, 2285-302	4.7	179

103	Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. *Annual Review of Pathology: Mechanisms of Disease*, **2012**, 7, 423-67	34	216
102	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. *Cell Cycle*, **2012**, 11, 3599-610	4.7	147
101	Ketone body utilization drives tumor growth and metastasis. *Cell Cycle*, **2012**, 11, 3964-71	4.7	113
100	Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1 and HIF2 in tumor-associated fibroblasts and human breast cancer cells. *Cell Cycle*, **2012**, 11, 3280-9	4.7	67
99	Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice: role of Cav1 in Shh heterotypic signaling and transendothelial migration. *Cancer Research*, **2012**, 72, 2262-74	10.1	19
98	Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. *Cell Cycle*, **2012**, 11, 3403-14	4.7	37
97	Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. *Cell Cycle*, **2012**, 11, 2545-56	4.7	95
96	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. *Cell Cycle*, **2012**, 11, 2272-84	4.7	96
95	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. *Cell Cycle*, **2012**, 11, 4402-13	4.7	64
94	Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. *Cell Cycle*, **2012**, 11, 253-63	4.7	55
93	Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFB activation in the tumor stroma. *Cell Cycle*, **2012**, 11, 4152-66	4.7	41
92	Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. *Oncotarget*, **2012**, 3, 798-810	3.3	90
91	Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer". *Cell Cycle*, **2011**, 10, 2440-9	4.7	165
90	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. *Cancer Biology and Therapy*, **2011**, 12, 924-38	4.6	134
89	Role of cholesterol in the development and progression of breast cancer. *American Journal of Pathology*, **2011**, 178, 402-12	5.8	202
88	Mitochondrial biogenesis drives tumor cell proliferation. *American Journal of Pathology*, **2011**, 178, 1949-52	5.8	48
87	Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. *International Journal of Biochemistry and Cell Biology*, **2011**, 43, 1045-51	5.6	189
86	Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. *Cell Cycle*, **2011**, 10, 3692-700	4.7	44

85	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. *Breast Cancer Research*, **2011**, 13, 213	8.3	136
84	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. *Cell Cycle*, **2011**, 10, 2504-20	4.7	193
83	Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?. *BMC Medicine*, **2011**, 9, 62	11.4	109
82	Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. *Cell Cycle*, **2011**, 10, 1784-93	4.7	103
81	Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. *Cell Cycle*, **2011**, 10, 1794-809	4.7	74
80	Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. *Cancer Biology and Therapy*, **2011**, 12, 1101-13	4.6	80
79	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. *Cell Cycle*, **2011**, 10, 4047-64	4.7	216
78	Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. *Cell Cycle*, **2011**, 10, 4250-5	4.7	65
77	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. *Cell Cycle*, **2011**, 10, 4065-73	4.7	96
76	Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. *Cell Cycle*, **2011**, 10, 2059-63	4.7	56
75	Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. *Cell Cycle*, **2011**, 10, 1271-86	4.7	229
74	Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. *Cell Cycle*, **2011**, 10, 1772-83	4.7	310
73	Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. *Cell Cycle*, **2011**, 10, 2521-8	4.7	83
72	Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. *Cell Cycle*, **2011**, 10, 2021-34	4.7	55
71	Caveolin-2-deficient mice show increased sensitivity to endotoxemia. *Cell Cycle*, **2011**, 10, 2151-61	4.7	20
70	Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. *Cell Cycle*, **2011**, 10, 2140-50	4.7	53
69	Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and AchillesR heel of tumor cells. *Cell Cycle*, **2011**, 10, 4208-16	4.7	129
68	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. *Cancer Biology and Therapy*, **2011**, 11, 383-94	4.6	100

67	Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. *Cancer Biology and Therapy*, **2011**, 12, 1085-97	4.6	118
66	Caveolinopathies: from the biology of caveolin-3 to human diseases. *European Journal of Human Genetics*, **2010**, 18, 137-45	5.3	151
65	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. *Cell Cycle*, **2010**, 9, 2412-22	4.7	112
64	Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. *Cancer Biology and Therapy*, **2010**, 10, 537-42	4.6	155
63	Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": a transcriptional informatics analysis with validation. *Cell Cycle*, **2010**, 9, 2201-19	4.7	188
62	CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. *Cancer Research*, **2010**, 70, 7489-99	10.1	55
61	Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. *Cancer Biology and Therapy*, **2010**, 10, 135-43	4.6	106
60	Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell Cycle*, **2010**, 9, 3506-14	4.7	429
59	HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. *Cell Cycle*, **2010**, 9, 3534-51	4.7	168
58	Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. *Cell Cycle*, **2010**, 9, 2423-33	4.7	208
57	The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. *Cell Cycle*, **2010**, 9, 4297-306	4.7	134
56	Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. *Cell Cycle*, **2010**, 9, 3256-76	4.7	341
55	The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. *Cell Cycle*, **2010**, 9, 1960-71	4.7	167
54	Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFB activation in the tumor stromal microenvironment. *Cell Cycle*, **2010**, 9, 3515-33	4.7	321
53	The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. *Cell Cycle*, **2010**, 9, 3485-505	4.7	215
52	Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. *American Journal of Pathology*, **2010**, 176, 1863-77	5.8	62
51	Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, AlzheimerB disease, and "Neuron-Glia Metabolic Coupling". *Aging*, **2010**, 2, 185-99	5.6	116
50	The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell Cycle*, **2009**, 8, 3984-4001	4.7	890

49	Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. *Cancer Biology and Therapy*, **2009**, 8, 1071-9	4.6	110
48	An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. *Cell Cycle*, **2009**, 8, 2420-4	4.7	123
47	Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. *Cell Cycle*, **2009**, 8, 1654-8	4.7	51
46	Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. *Laboratory Investigation*, **2009**, 89, 614-23	5.9	67
45	An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. *American Journal of Pathology*, **2009**, 174, 2023-34	5.8	252
44	Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. *American Journal of Pathology*, **2009**, 174, 1650-62	5.8	62
43	Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. *American Journal of Pathology*, **2009**, 174, 613-29	5.8	15
42	Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. *American Journal of Pathology*, **2009**, 174, 746-61	5.8	101
41	Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. *American Journal of Pathology*, **2009**, 174, 1172-90	5.8	49
40	Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation. *Cell Cycle*, **2009**, 8, 1396-401	4.7	14
39	Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro. *Laboratory Investigation*, **2008**, 88, 275-83	5.9	32
38	Regulation of Cripto-1 signaling and biological activity by caveolin-1 in mammary epithelial cells. *American Journal of Pathology*, **2008**, 172, 345-57	5.8	20
37	Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. *Cell Cycle*, **2008**, 7, 2257-67	4.7	69
36	Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. *Cancer Biology and Therapy*, **2008**, 7, 1212-25	4.6	122
35	Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. *Arthritis and Rheumatism*, **2008**, 58, 2854-65		137
34	Phenotypic characterization of hypomyelination and congenital cataract. *Annals of Neurology*, **2007**, 62, 121-7	9.4	37
33	Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. *Cell Cycle*, **2007**, 6, 1242-8	4.7	63
32	Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. *Cancer Biology and Therapy*, **2007**, 6, 1263-8	4.6	40

31	Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. *American Journal of Pathology*, **2007**, 170, 316-33	5.8	54
30	Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. *Cancer Biology and Therapy*, **2006**, 5, 292-7	4.6	24
29	A novel role for caveolin-1 in B lymphocyte function and the development of thymus-independent immune responses. *Cell Cycle*, **2006**, 5, 1865-71	4.7	39
28	Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. *Cancer Research*, **2006**, 66, 10647-51	10.1	53
27	Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. *American Journal of Physiology - Cell Physiology*, **2006**, 290, C577-82	5.4	53
26	Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. *American Journal of Pathology*, **2006**, 168, 292-309	5.8	62
25	Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. *American Journal of Pathology*, **2006**, 168, 1998-2013	5.8	85
24	Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. *American Journal of Pathology*, **2006**, 169, 1784-801	5.8	73
23	Identification of phosphocaveolin-1 as a novel protein tyrosine phosphatase 1B substrate. *Biochemistry*, **2006**, 45, 234-40	3.2	36
22	SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. *Trends in Endocrinology and Metabolism*, **2006**, 17, 150-8	8.8	35
21	Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract. *Nature Genetics*, **2006**, 38, 1111-3	36.3	73
20	Impaired phagocytosis in caveolin-1 deficient macrophages. *Cell Cycle*, **2005**, 4, 1599-607	4.7	51
19	Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs. muscle cells. *American Journal of Physiology - Cell Physiology*, **2005**, 288, C677-91	5.4	52
18	Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. *Cell Cycle*, **2005**, 4, 1817-25	4.7	62
17	ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracisRthree sites of entry: implications for the pathogenesis of anthrax infection. *American Journal of Physiology - Cell Physiology*, **2005**, 288, C1402-10	5.4	90
16	Caveolin-1-deficient mice have an increased mammary stem cell population with upregulation of Wnt/beta-catenin signaling. *Cell Cycle*, **2005**, 4, 1808-16	4.7	64
15	Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27). *Biochemistry*, **2004**, 43, 13694-706	3.2	21
14	Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. *American Journal of Physiology - Cell Physiology*, **2003**, 285, C1150-60	5.4	33

13	Localization of phospho-beta-dystroglycan (pY892) to an intracellular vesicular compartment in cultured cells and skeletal muscle fibers in vivo. *Biochemistry*, **2003**, 42, 7110-23	3.2	43
12	Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. *American Journal of Pathology*, **2003**, 163, 1663-75	5.8	104
11	Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. *American Journal of Pathology*, **2003**, 163, 2619-34	5.8	29
10	Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. *American Journal of Pathology*, **2003**, 162, 2029-39	5.8	137
9	Intracellular retention of glycosylphosphatidyl inositol-linked proteins in caveolin-deficient cells. *Molecular and Cellular Biology*, **2002**, 22, 3905-26	4.8	80
8	Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. *American Journal of Pathology*, **2002**, 160, 265-70	5.8	104
7	Tyrosine phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 domain containing proteins. *Biochemistry*, **2001**, 40, 14585-92	3.2	82
6	Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family members. *Journal of Biological Chemistry*, **2000**, 275, 38048-58	5.4	149
5	Localization of the human caveolin-3 gene to the D3S18/D3S4163/D3S4539 locus (3p25), in close proximity to the human oxytocin receptor gene. Identification of the caveolin-3 gene as a candidate for deletion in 3p-syndrome. *FEBS Letters*, **1999**, 452, 177-80	3.8	19
4	Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. *Biochemical and Biophysical Research Communications*, **1999**, 261, 547-50	3.4	85
3	Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. *Nature Genetics*, **1998**, 18, 365-8	36.3	493
2	Identification and characterization of a new human cDNA from chromosome 21q22.3 encoding a basic nuclear protein. *Human Genetics*, **1998**, 102, 289-93	6.3	27
1	Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. *American Journal of Human Genetics*, **1998**, 63, 1578-87	11	159